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REVIEW ARTICLE
Routes and mechanisms of extracellular vesicle uptake
Laura Ann Mulcahy*, Ryan Charles Pink and David Raul Francisco Carter
Department of Biological and Medical Science, Faculty of Health and Life Sciences,
Oxford Brookes University, Oxford, UK
Extracellular vesicles (EVs) are small vesicles released by donor cells that can be taken up by recipient
cells. Despite their discovery decades ago, it has only recently become apparent that EVs play an important role
in cell-to-cell communication. EVs can carry a range of nucleic acids and proteins which can have a significant
impact on the phenotype of the recipient. For this phenotypic effect to occur, EVs need to fuse with target cell
membranes, either directly with the plasma membrane or with the endosomal membrane after endocytic
uptake. EVs are of therapeutic interest because they are deregulated in diseases such as cancer and they could
be harnessed to deliver drugs to target cells. It is therefore important to understand the molecular mechanisms
by which EVs are taken up into cells. This comprehensive review summarizes current knowledge of EV uptake
mechanisms. Cells appear to take up EVs by a variety of endocytic pathways, including clathrin-dependent
endocytosis, and clathrin-independent pathways such as caveolin-mediated uptake, macropinocytosis,
phagocytosis, and lipid raftmediated internalization. Indeed, it seems likely that a heterogeneous population
of EVs may gain entry into a cell via more than one route. The uptake mechanism used by a given EV may
depend on proteins and glycoproteins found on the surface of both the vesicle and the target cell. Further
research is needed to understand the precise rules that underpin EV entry into cells.
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E
xtracellular vesicles (EVs) are small spherical pack-
ages that are released by cells into the extracellu-
lar environment (1). EVs consist of a lipid bilayer
membrane that encases a small organelle-free cytosol.
Suspended in the aqueous core, or associated with the
lipid casing, are proteins and nucleic acids derived from
the cell of origin (2,3). EVs can be categorized further
depending upon where in the cell they originate; for
example, vesicles that are derived from multi-vesicular
bodies (MVBs) are referred to as exosomes and those
from the plasma membrane as microvesicles (1). It has
become evident that EVs are important factors involved
in a range of physiological processes including intercel-
lular exchange of proteins and RNA (4,5), induction
of angiogenesis (6), bystander effect (7) and immune
regulation (2,8,9).
EVs protect their cargo from enzymatic degrada-
tion during transit through the extracellular environment
(1012). Upon release of their functionally active mRNA
and microRNA load inside the recipient cell, EV contents
can regulate gene expression through de-novo translation
and post-translational regulation of target mRNAs (3).
Changes in miRNA levels are particularly important
during development (13) and stress response (14), and
EVs may play a role in their exchange between cells (7).
EVs can also exert effects on cells by stimulating specific
signalling pathways (15). The ability of EVs to alter the
transcriptome and signalling activity within recipient
cells allows them to induce specific phenotypic changes
(1618). Indeed, alterations in EV activity may be a
feature of certain pathologies, including cancer (19).
There is also interest in EVs as potential therapeutics.
By harnessing the capability of EVs to transfer their
contents into target cells it may be possible to convert
these vesicles into vehicles for the delivery of therapeutic
proteins, RNA molecules and drugs (20,21). Given their
emerging roles in normal physiological processes and in
disease, and their therapeutic potential, it is important to
understand the molecular mechanisms of EV release by
donor cells and the processes by which they are taken up

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by recipient cells. In this review we will outline the ways in
which EV uptake can be studied and review the current
understanding of how EVs enter target cells.
Evidence for EV uptake
Both direct and indirect evidence exists to suggest that
EVs are internalized into recipient cells. EVs have been
shown to transfer functional mRNA and miRNA from
mouse to human mast cells where mouse proteins were
identified in the recipient human cells (3). EV-mediated
siRNA delivery has been shown to knockdown target gene
expression (20), and administration of EVs laden with
luciferin substrate to luciferase expressing cells resulted in
production of bioluminescence (22). These results imply
that merging of the EV cytosol and the cytoplasmic com-
partment had occurred through membrane fusion at the
plasma membrane or by uptake through other pathways
followed by fusion with the endosomal membrane (22).
EV uptake can also be visualized directly. The most
common method for detecting EV uptake involves the
use of fluorescent lipid membrane dyes to stain EV
membranes. Examples of such dyes include PKH67
(2329), PKH26 (28,3032), rhodamine B (also known
as R18) (22,3338), DiI (30,33,39) and DiD (40) which
are lipophilic dyes. Membrane permeable chemical com-
pounds are also used to stain EVs. These include carboxy-
fluorescein succinimidyl ester (CFSE) (3946) and
5(6)-carboxyfluorescein diacetate (CFDA) (46). These
compounds become confined to the cytosolic lumen and
fluoresce as a consequence of esterification. Subsequent
entry of EVs into recipient cells can be measured using
methods such as flow cytometry and confocal microscopy.
To distinguish between internalized and surface-bound
fluorescent EVs, the surface of the cell can be stripped by
treatment with acid (27) or trypsin (32). Such experiments
suggest that many cells do indeed internalize EVs.
One potential issue with membrane-binding dyes is
that the presence of the fluorescent molecules could
affect the normal behaviour of EVs. Uptake of EVs has
been observed with many different lipid-binding dyes,
suggesting that such molecules do not affect the coarse
internalization of vesicles; nevertheless, further experi-
mentation is needed to verify whether the precise biolo-
gical behaviour of EVs is affected by dyes. Another
consideration is that the distinct types of dyes may lead
to different patterns of cellular staining following uptake.
Lipophilic dyes associate with lipids, whereas molecules
that become esterified in the lumen remain in solution;
their fate is thus bound with membrane and cytosol,
respectively. Another potential limitation of the use of
such lipophilic dyes is the leaching of the fluorescent
molecules from EVonto cellular membranes, leading to a
pattern of internalization that is due to normal membrane
recycling rather than EV uptake. However, this seems un-
likely given the numerous reports of molecular inhibitors
that appear to prevent EV uptake (Table I). Other control
experiments, such as incubation of cells with excess
unlabelled EVs and direct measurement of the rate of
transfer of fluorescence between EVs also support the idea
that the increased fluorescence in recipient cells is due
to specific uptake of EVs rather than non-specific dye
leaching (25).
It should also be appreciated, however, that almost
all studies have relied on fluorescence microscopy, which
has limited resolution because the wavelength of visible
light is approximately 390700 nm; therefore single EVs
or clusters of vesicles that are less than 390 nm in dia-
meter cannot be distinguished. This should not affect the
assessment of EV uptake in general but may affect the
visualization and dynamic localization analysis of indivi-
dual EVs. EVs can be visualized in a potentially more
specific way via the use of fluorescent proteins fused with
vesicular proteins. For example, CD9 and CD63 are
tetraspanin proteins found enriched in EVs which, when
tagged with GFP, can be used to show uptake and pro-
cessing of vesicles in cells (10,47,48). A caveat of such
experiments is the assumption the fluorescent protein tag
does not affect the normal function or trafficking of the
tetraspanin protein, and does not therefore potentially
alter the behaviour of the EV during uptake.
The evidence that EVs can enter cells and deliver their
cargo is overwhelming. The mechanism responsible for
EV internalization into cells, however, has raised great
debate in the literature. Various mechanisms for EV
uptake have been proposed (Fig. 1), including clathrin-
mediated endocytosis (CME), phagocytosis, macropino-
cytosis and plasma or endosomal membrane fusion. The
roles of lipid rafts and specific proteinprotein interac-
tions have also been studied. A range of techniques can
be used in conjunction with EV uptake assays to tease out
these molecular mechanisms. This includes the use of
antibodies to test the role of specific ligands or receptors,
and the use of chemical inhibitors to block specific up-
take pathways. The results of such studies have shed
much light on the routes by which EVs enter cells.
Protein interactions
The EV uptake mechanisms involve protein interactions
that facilitate subsequent endocytosis (9,25,26,30,49).
Proteinase K treatment of EVs was shown to significantly
reduce their uptake by ovarian cancer cells which strongly
supports the role of proteins in the EV uptake pathway
(41). Many EV proteins have been shown to interact with
membrane receptors on target cells (50,51). Hence, EV
uptake is most likely dependent upon the signalling status
of recipient cells and of the protein complement of the
vesicle. In the literature there is a growing list of specific
proteinprotein interactions that mediate EV attachment
and uptake into cells. Many of these interactions have
been elucidated by the use of specific antibodies that
Laura Ann Mulcahy et al.
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Table I. Compounds, chemicals and peptides used to inhibit EV uptake
Pathways blocked Inhibitor Target Treatment recipient
Endocytosis Heparin Heparan sulphate proteoglycans Glioblastoma multiforme primary tumour
cells (25); SW-780 bladder cancer cells (32);
Endocytosis a-difluoromethylornithine
(DFMO)
Heparan sulphate proteoglycans Glioblastoma multiforme primary tumour
cells (25);
Endocytosis Asialofetuin Galectin-5 Macrophages (24);
Endocytosis Human receptorassociated
protein (RAP)
CD91 Dendritic cells (79);
Endocytosis RGD (Arg-Gly-Asp) peptide Fibronectin Macrophages (23); Dendritic cells (30);
Endocytosis Ethylenediaminetetra acetic
acid (EDTA)
Calcium Macrophages (24); Dendritic cells (30,44);
bone marrowderived dendritic cells (22);
Endocytosis Cytochalasin D Actin Human macrophages (23); SKOV-3 ovarian
cancer cells (41); RAW-264.7 macrophages
(27); Microglia (28); Dendritic cells (30,44);
Bone marrowderived dendritic cells (22);
human A549 alveolar epithelial cells (77);
Human umbilical cord endothelial cells (26);
HeLa cells (26);
Endocytosis Cytochalasin B Actin Macrophages (24);
Endocytosis Latrunculin A Actin Human umbilical cord endothelial cells (26);
HeLa cells (26);
Endocytosis Latrunculin B Actin RAW-264.7 macrophages (27);
Clathrin- and
caveolin-dependent
endocytosis
NSC23766 Dynamin Microglia (28);
Clathrin- and
caveolin-dependent
endocytosis
Dynasore Dynamin-2 Macrophages (24); Microglia (28);
Clathrin-dependent
endocytosis
Chlorpromazine Dopamine receptors, serotonin
receptors, histamine receptors,
a1- and a2-adrenergic receptors
and M1 and M2 muscarinic
acetylcholine receptors
SKOV-3 ovarian cancer cells (41);
RAW-264.7 macrophages (27);
Macropinocytosis 5-(N-Ethyl-N-
isopropyl)amiloride (EIPA)
Sodium/proton exchanger SKOV-3 ovarian cancer cells (41);
RAW-264.7 macrophages (27);
Macropinocytosis Amiloride Sodium/proton exchanger Microglia (28);
Macropinocytosis Bafilomycin A
Monensin and Chloroquine
H()-ATPase activity (increase
pH)
Microglia (28);
Phagocytosis and
macropinocytosis
Annexin-V Phosphatidylserine Microglia (28,31); Ovarian cancer patient
ascites-derived EVs (10); Neuro-2A mouse
neuroblastoma cells (31);
Phagocytosis Wortmannin Phosphoinositide 3-kinases (PI3Ks) RAW-264.7 macrophages (27);
Phagocytosis LY294002 Phosphoinositide 3-kinases (PI3Ks) RAW-264.7 macrophages (27);
Lipid raftmediated
endocytosis
Methyl-b-cyclodextrin
(MbCD)
Cholesterol SKOV-3 ovarian cancer cells (41);
RAW-264.7 macrophages (27); BT-549
breast cancer cells (47); Human umbilical
cord endothelial cells (26); U87-MG
glioblastoma cells (26);
Lipid raftmediated
endocytosis
Filipin Cholesterol Bone marrowderived dendritic cells (22);
Melanoma cells (34); Human umbilical cord
endothelial cells (26);
Lipid raftmediated
endocytosis
Simvastatin Cholesterol Human umbilical cord endothelial cells (26);
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recognize ligands or receptors, leading to a steric block
that prevents their interaction. Here we review some of the
proteins shown to participate in EV uptake. It should be
noted that in some cases the phenotypic effects of EVs do
not require internalization of the vesicle (see conclusions
and future directions); therefore in our discussion we focus
on examples where the involvement of specific protein
protein interactions is evidenced by the effect on direct EV
uptake or binding, rather than by functional outputs.
Tetraspanins
Tetraspanins are membrane proteins which have numer-
ous functions including cell adhesion, motility, activation
and proliferation (reviewed in (52)). Tetraspanins are
highly abundant on the EV surface which suggests they
may have a role in EV function (53,54). CD63, CD9
and CD81 are well-established markers of EVs (2,5458).
CD9 and CD81 are tetraspanins involved in oocyte-
spermatozoa and phagocyte fusion (56,57,59,60); in addi-
tion, numerous viruses and parasites require interaction
with tetraspanins in order to enter the cell and replicate
(61). Due to the high abundance of tetraspanins and
their roles in cell adhesion it is possible that EV uptake
could occur through similar processes (37). Tetraspanin-
enriched microdomains (TEMs) are clusters of tetraspa-
nins, adhesion molecules and transmembrane receptor
proteins located in raft-like structures in the plasma
membrane (52). TEMs have been shown to be involved in
a number of processes, including vesicular and cellular
fusion (52,62,63), leading to the hypothesis that they have
a role in EV-cell binding (6467).
Treatment of recipient cells with antibodies against
the tetraspanins CD81 or CD9 can reduce uptake of EVs
by dendritic cells (30). Tspan8 is a tetraspanin known to
complex with integrins (35). Cells over-expressing Tspan8
released EVs bearing a Tspan8-CD49d complex, the pre-
sence of which contributed to EV uptake by rat aortic
endothelial cells (35). Antagonistic antibody treatment
suggests that CD106 strengthens this interaction (35).
In addition, it was discovered that EVs that presented
Tspan8-CD49d complex on their surface were readily
internalized by endothelial cells and pancreatic cells where
intercellular adhesion molecule 1 (ICAM-1, also known
as CD54) was the major ligand (37). These data point to a
role for tetraspanins in the internalization of EVs.
Integrins and immunoglobulins
The observation that EVs play a role in the immune
response has garnered much interest in the roles of in-
tegrins and immunoglobulins in the interaction between
vesicles and cells. These proteins are involved in a range
of functions, including cell-to-cell adhesion, cell signal-
ling, leukocyte transendothelial transmigration and anti-
gen presentation (68). Indeed, several reports in the
literature suggest they may also be involved in EV uptake.
Antibodies that mask the binding sites of CD11a or
its ligand ICAM-1 can reduce dendritic cell uptake of
EVs (30). Similar results were observed after blocking
the integrins av (CD51) and b3 (CD61) on the dendritic
cell surface (30). CD11a is a subunit of the lymphocyte
function-associated antigen 1 (LFA-1), which interacts
with ICAM-1 to regulate critical pathways in the immune
response (69). Inducing a high-affinity state of LFA-1 on
resting T-cells using manganese chloride treatment was
sufficient to increase EV binding in a dose-dependent
manner (70). Antagonistic antibody treatment inhibited
this process (44,45,70). Naı¨ve T-cells have been shown
to internalize EVs through a mechanism requiring the
participation of T-cell receptor (TCR), CD28 and LFA-1
(71). It was also shown that dendritic cellderived EVs
were internalized via TCR-major histocompatibility com-
plex (MHC) and LFA-1ICAM-1 interactions in CD4
cells (44). Similarly dendritic cells take up CD8T-cell
EVs in an endocytic pathway that requires pMHC I/TCR
and LFA-1-ICAM-1 interactions (43). The protein milk
fat globule-epidermal growth factor 8 (MFG-E8) is
thought to enhance the phagocytic uptake of apoptotic
cells by binding phosphatidylserine (PS) via 1 domain
and with cell surface integrin proteins CD51 and CD61
via a second domain (72). Perturbation of MFG-E8 leads
to alterations in the rate of EV uptake (30). These results
highlight the emerging roles of proteinprotein interac-
tions in vesicle uptake, particularly in cells of the immune
system.
Table I (Continued )
Pathways blocked Inhibitor Target Treatment recipient
Lipid raftmediated
endocytosis
Fumonisin B1 and
N-butyldeoxynojirimycin
hydrochloride
Glycosphingolipid Pre-treatment of EV-producing Jurkat
cells (80); HEK-293T kidney cells (80);
Lipid raftmediated
endocytosis
U0126 ERK1/2 Human umbilical cord endothelial cells (26),
HeLa cells (26); Mouse embryonic
fibroblasts (26);
Membrane fusion Proton pump inhibitor
(AstraZeneca)
Sodium reabsorption (decrease
pH)
Melanoma cells (34);
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A role for proteoglycans
Proteoglycans are proteins with significant carbohydrate
components. For example, the heparin sulphate proteo-
glycans (HSPGs) are proteins with sulphated glycosami-
noglycan polysaccharides attached. Various complexes,
including viral particles and lipoproteins, use HSPGs to
help gain entry into cells (73). Fluorescently labelled EVs
co-localize with internal vesicles containing GFP-linked
syndecan or glypican (the 2 main types of HSPG) inside
recipient cells (25). Treatment of cells with a heparin
sulphate mimetic reduced EV uptake in a dose-dependent
manner (25,32). Cells whose ability to produce normal
levels and structures of HSPGs, either because of genetic
defects or chemical inhibition, showed a reduced ability
to internalize EVs (25). These results are consistent with a
role for proteoglycans in the uptake of EVs. Interestingly,
treatment of EVs with heparinase to remove surface
proteoglycans had no effect on uptake, suggesting that it
is the presence of HSPGs on the cell surface that are
important for mediating vesicular entry (25).
Lectins
DC-SIGN is a C-type lectin receptor (a receptor able to
recognize and internalize glycoprotein ligands) that can
trigger phagocytic entry for a range of molecules, includ-
ing viruses and bacteria (74). One potential ligand is the
MUC1 protein found on epithelial cells and on the sur-
face of EVs derived from breast milk. The recruitment
of these EVs by monocyte-derived dendritic cells was
blocked by antibodies specific to DC-SIGN on the reci-
pient cell surface (29). Another C-type lectin, DEC-205,
also appears to mediate entry of EVs into dendritic cells;
vesicle uptake was inhibited by treatment with DEC-205-
specific antibodies or by incubation with excess man-
nose (a sugar recognized by DEC-205) (44). Chelation of
calcium with ethylenediaminetetraacetic acid (EDTA)
Fig. 1. Pathways shown to participate in EV uptake by target cells. EVs transport signals between cells. EVs have been shown to be
internalized by cells through phagocytosis, clathrin- and caveolin-mediated endocytosis. There is also evidence to support their
interaction with lipid rafts resulting in EV uptake. Lipid rafts are involved in both clathrin- and caveolin-mediated endocytosis. EVs can
be internalized by macropinocytosis where membrane protrusions or blebs extend from the cell, fold backwards around the EVs and
enclose them into the lumen of a macropinosome; alternatively EVs are macropinocytosed after becoming caught in membrane ruffles.
EVs may also deliver their protein, mRNA and miRNA cargo by fusion with the plasma membrane. Alternatively, intraluminal EVs
may fuse with the endosomal limiting membrane following endocytosis to enable their EV contents to elicit a phenotypic response.
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significantly reduced EV uptake by dendritic cells (44),
and also in macrophages (24); supporting the hypothesis
that the EV uptake is facilitated by C-type lectin/C-
type lectin receptor interactions. Interestingly, ovarian
cancerderived EVs were found to be enriched in specific
mannose- and sialic acid containing glycoproteins (41).
Sialic acid removal caused a small but non-significant
increase in uptake (41). Galectin-5, a lectin with binding
specificity towards certain glycoproteins, can be found
associated with EVs (24). Incubating EVs with cells in the
presence of excess galectin-5 significantly reduced vesicu-
lar internalization (24). When asialofetuin (a glycoprotein
that can bind galectin-5) was included in the uptake assay
the entry of EVs was abrogated (24). These results are all
consistent with a role for glycoproteins and proteoglycans
in the uptake of EVs.
Endocytosis
Most experimental evidence suggests that EVs are usually
taken up into endosomal compartments via endocytosis
(22,30,41). Uptake can be extremely rapid, with EVs being
identified inside cells from as early as 15 minutes after
initial introduction (27,48). A number of research groups
have shown that when cells are incubated at 48C their
capacity to internalize EVs is dramatically reduced
suggesting that uptake is an energy-requiring process
(25,30,33,38,41,46). Further evidence that internalization
is not a passive process is provided by observations that
EVs are not taken up by cells fixed in paraformaldehyde
(28,36). Cytochalasin D is a metabolite known to depoly-
merize the actin filament network resulting in inhibition
of endocytic pathways (75,76). Cytochalasin D treatment
has been shown, on several occasions in various cell
types, to significantly reduce, but not completely prevent,
EV uptake in a dose dependent manner (22,23,2628,
30,41,44,77). Taken together these results suggest that
EV uptake is an energy-dependent process that requires
a functioning cytoskeleton, both of which are indicative
of endocytic pathways. However, one implication of the
frequent failure to completely abrogate internalization
following treatment with any given inhibitor is that
EV uptake occurs through more than one mechanism
(24,27,30,40,41,44,77).
Endocytosis is an umbrella term for a range of mole-
cular internalization pathways (78). By using a range of
inhibitors to block specific pathways (Table I), antibodies
to prevent receptorligand interactions (Table II) and
other experimental techniques such as RNAi to knock-
down certain genes the role of the endocytic processes
responsible for EV uptake are being elucidated. Roles for
many of these subdivisions have been shown, including
macropinocytosis (28,41), phagocytosis (22,27,41,82) and
CME (41) (Fig. 1).
Clathrin-mediated endocytosis
CME involves cellular internalization of molecules
through progressive and sequential assembly of clathrin-
coated vesicles that contain a range of transmembrane
receptors and their ligands. The clathrin-coated vesicles
strategically deform the membrane which collapses into a
vesicular bud, matures and pinches off. The subsequent
intracellular vesicle undergoes clathrin un-coating and
then fuseswith the endosomewhere it deposits its contents
(83). Various studies implicate CME in the uptake of EVs.
Chlorpromazine prevents formation of clathrin-coated
pits at the plasma membrane (84). CME inhibition by
chlorpromazine decreased uptake of EVs by ovarian
cancer recipient cells (41) and phagocytic recipient cells
(27). Dynamin2 is aGTPase required for the CMEprocess
(85,86). Dynamin2 is recruited to nascent clathrin-coated
pits where it forms a collar-like structure at the neck of
deeply invaginated clathrin-coated pits (8789). GTP-
hydrolysis mediated changes in dynamin2 conformation
lead tomembrane fission and clathrin-coated vesicle release
(86,9092). Dynamin2 also facilitates membrane binding
(9395) and membrane curvature (96) during CME. In
phagocytic cells, inhibition of dynamin2 (85,86) prevented
almost all EV internalization activity (24,27,28). A small
percentage of EVs were also shown to co-localize with
clathrin during uptake in macrophages (27). Epidermal
growth factor receptor pathway substrate clone 15
(EPS15) is a component of clathrin-coated pits that is
ubiquitously associatedwith AP-2 adaptor complex which
is an integral component of the clathrin coat (97).
Expression of a dominant-negative mutant of EPS15
inhibits CME and leads to a reduction in EV uptake
(27). These results suggest that CME plays at least some
part in EV uptake.
Caveolin-dependent endocytosis
CME has been extensively studied for many years, but
it is becoming increasingly apparent that a plethora of
clathrin-independent endocytotic pathways exist in eukar-
yotic cells (78). One suchmechanism is caveolin-dependent
endocytosis (CDE). Caveolae are small cave-like invagina-
tions in the plasma membrane which, like clathrin-coated
pits, can become internalized into the cell. Caveolae
are sub-domains of glycolipid rafts of the plasma mem-
brane that are rich in cholesterol, sphingolipids and
caveolins; hence, CDE is sensitive to cholesterol depletion
agents such as filipin, and methyl-b-cyclodextrin (MbCD)
(98100). Caveolin-1 is a protein that is required and
sufficient for the formation of caveolae (78) and can be
found clustered within such membrane invaginations.
Oligomerization of caveolins (facilitated by caveolin oli-
gomerization domains) mediates formation of caveolin-
rich rafts in the plasma membrane. The increased levels
of cholesterol accompanied by attachment of caveolin
Laura Ann Mulcahy et al.
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scaffolding domains to the plasma membrane and dyna-
min2 (also required in CME) activity enable assembly
and expansion of caveolar endocytic vesicles (78,100,101).
Dynamin2, can be blocked by the specific inhibitor
dynasore (102). Blocking dynamin2 leads to significantly
reduced internalization of exosomes (103) or larger
microvesicles (24,104), suggesting a role for caveolae-
mediated endocytosis in vesicular uptake. However, be-
cause dynamin2 is also required for CME it is not possible
to rule out a role for clathrin-coated vesicles in these
experiments (105). Specific knockdown of the CAV1 gene
leads to reduced caveolin-1 protein and significantly
impaired uptake of EVs (103). Paradoxically, knockout
of CAV1 in mouse embryonic fibroblast cells leads to
increased EV uptake (26). CAV1 null mice show pheno-
typic changes in vasculature but are viable (106), suggest-
ing that either CAV1 is not essential for full EV uptake
or that the ability to internalize vesicles via CDE is not
essential for viability. Nevertheless, taken together the
results described above imply some kind of function for
caveolae-mediated endocytosis in EV uptake, though the
precise role of this pathway may vary between cell and EV
types.
Macropinocytosis
Macropinocytosis is an endocytic uptake pathway that
involves the formation of invaginated membrane ruffles
that then pinch off into the intracellular compartment.
The vesicles carry extracellular fluid and components
sampled from the region around the membrane ruffles
(78). Ruffled extensions of the plasma membrane pro-
trude from the cell surface and encompass an area of
extracellular fluid, subsequently this area of extracellular
fluid is internalized entirely as a result of fusion of the
membrane protrusions with themselves or back with the
plasma membrane (Fig. 1) (107). The mechanism is
similar to that of phagocytosis, however, direct contact
with the internalized material is not required. This mecha-
nism is rac1-, actin- and cholesterol-dependent and
requires Na /H exchanger activity (108). Cholesterol
is required for the recruitment of activated rac1 to sites
of macropinocytosis (109). Phosphatidylinositol-3-kinase
(PI3K), ras, and src activities have also been shown
to stimulate macropinocytosis (78). Rac1 is a GTPase
which not only has a major role in macropinocytosis
(110), but also in regulation of cell growth, cytoskele-
tal reorganization, protein kinase activation (111) and
epithelial-to-mesenchymal transition (EMT) in cancer
(112). Abrogation of macropinocytosis by inhibiting
the Na /H exchanger results in significantly reduced
oligodendrocyte-derived EV uptake by microglia (28). A
small molecule inhibitor of rac1, NSC23766, also inhi-
bited EV uptake by microglia (28). The alkalinizing drugs
bafilomycin A, monensin and chloroquine all inhibited
microglial internalization of EVs, consistent with a role
for the acidification of vacuoles in macropincytosis (28).
However, other studies using inhibitors do not find a role
for macropinocytosis in the uptake of EVs (25,27,103).
These findings suggest that macropinocytosis is either
a minor pathway used by cells to internalize EVs, or a
mechanism used in specific cell types.
Phagocytosis
The process of phagocytosis involves the internalization
of opsonized particulate matter, including bacteria and
fragments of apoptotic cells. This function is often per-
formed by specialized cells such as macrophages (78).
Phagocytosis is a receptor-mediated event that involves
the progressive formation of invaginations surround-
ing the material destined for internalization, with or with-
out the participation of enveloping membrane extensions
(as required for macropinocytosis) (78,107). Generally,
phagocytosis is employed to internalize larger particles.
Table II. Antibodies used to block EV uptake
Target Treatment recipient
ICAM-1 Dendritic cells (30); lymph node cells and spleen
cells (38);
LFA-1 Dendritic cells (43,44); CD8 ConA T cells (45);
T cells (70);
TIM-4 RAW-264.7 macrophages (27); BaF3 bone marrow
pro-B cells (79);
MFG-E8 Dendritic cells (30);
DC-SIGN Monocyte-derived dendritic cells (29);
DEC205 Dendritic cells (44);
H-2Kb Dendritic cells (43);
Tspan8 Rat aortic endothelial cells (35);
CD9 Dendritic cells (30); Lung fibroblasts (35); rat
pancreatic adenocarcinoma
BSp73ASML (ASML) cell-derived EVs (38);
CD11a Dendritic cells (30);
CD11b Lymph node cells and spleen cells (38);
CD11c Lymph node cells and spleen cells (38);
CD44 Lymph node cells and spleen cells (38);
CD49c Lung fibroblasts (35);
CD49d Rat aortic endothelial cells (35); lymph node cells
and spleen cells (38);
av (CD51) Dendritic cells (30);
b3 (CD61) Dendritic cells (30);
CD62L Lymph node cells and spleen cells (38);
CD81 Dendritic cells (30); rat pancreatic
adenocarcinoma BSp73ASML (ASML) cell-derived
EVs (38);
CD91 Dendritic cells (79);
CD106 Rat aortic endothelial cells (35);
CD151 Lung fibroblasts (35);
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However, it has been shown that particles as small as
85 nm in diameter have been internalized by phagocytosis;
therefore it is possible that EVs could be internalized
via this route (113). In one study the EVs released by
leukaemia cells were shown to be taken up efficiently by
macrophages but were not internalized by other cell types
(27). PI3Ks play an important role in phagocytic pro-
cesses, particularly in enabling membrane insertion into
forming phagosomes (114). The PI3K inhibitors wort-
mannin and LY294002 were used to assess the necessity of
functional PI3Ks in EV uptake. Both drugs inhibited EV
uptake in a dose dependantmanner (27). Furthermore, the
EVs co-localized with fluorescent phagosome tracers (27).
Dendritic cellderived EVs were labelled with pHrodo, a
dye that becomes fluorescent red at the phagosome pH.
Acceptor dendritic cells treated with pHrodo-EVs emitted
red fluorescence confirming that dendritic cells can phago-
cytose EVs (22). Taken together these results implicate
phagocytosis in EV uptake.
Phosphatidylserine (PS) is essential in initiating the
removal of apoptotic bodies by phagocytosis (115) and is
used by some viruses to enter cells by macropinocytosis
(116). PS is typically located on the inner leaflet of the
plasma membrane; however, EVs are enriched for PS on
their outer-membrane (117) whichmay facilitate entry into
cells. Incubation of macrophages with an antibody that
masks TIM4, a receptor involved in PS-dependent phago-
cytosis (27,81), leads to reduced uptake of EVs (27).
Treatment of dendritic cells with a competitive soluble
PS analogue also reduced EV uptake (30). Treatment of
EVs with annexin-V (a protein that binds PS) reduces the
uptake of EVs into macrophages (31) and natural killer
cells (70). Phagocytic and macropinocytic uptake of EVs
may therefore be, at least in part, triggered by the PS found
on the outer leaflet of EV membranes.
Involvement of lipid rafts
Lipid rafts are microdomains within the plasma mem-
brane with altered phospholipid compositions. They are
rich in protein receptors and sphingolipids such as sphin-
gomyelin. They act as organizing centres for the assembly
of signalling molecules, they affect membrane fluidity
and mediate membrane protein trafficking (100). Com-
ponents of lipid rafts are highly ordered and more tightly
packed than the surrounding bilayer, consequently they
are less fluid but float freely in the plasma membrane
(118). Endocytosis that is clathrin-independent largely
requires cholesterol, which is found enriched in lipid
rafts. Lipid rafts are known to contribute to viral particle
uptake by mediating glycoprotein binding and adjusting
the physicochemical and mechanical properties of the
membrane (119). These rafts can be found in the invagi-
nations formed by caveolin-1 or in planar regions of the
plasma membrane marked by another family of proteins
called flotillins (120). Flotillins associate with lipid rafts
and mediate endocytosis independent of clathrin and
caveolin (121125). Flotillins have been found to bind
to GPI-anchored proteins during their internalization
(121,122,125). It is possible that EVs are internalized by
cells through lipid raft domains.
To test the role of lipid rafts in EV uptake, a range
of inhibitors have been employed. EV uptake was
significantly reduced in dendritic cells when EV-
producing cells were pre-treated with fumonisin B1 and
N-butyldeoxynojirimycin hydrochloride (80), compounds
which decrease glycosphingolipid composition in the plasma
membrane by preventing its biosynthesis (126,127). This
suggests that sphingolipids within the EV have an im-
portant role in binding and endocytosis, possibly through
cholesterol-rich microdomains in dendritic cells (80). EV
uptake was prevented following pre-treatment of reci-
pient cells with the cholesterol reducing agents MbCD
(26,27,41,47), filipin (22,26,34) and simvastatin (26).
These treatments disrupt lipid raftmediated endocytosis
but may also affect EV membrane integrity, causing the
reduced EV uptake effects observed. Co-localization can
be observed between fluorescently labelled EVs and
cholera toxin B (a protein known to be internalized via
lipid rafts) in recipient cells (26,47). Poor co-localization
was observed between caveolin-1 and labelled EVs, sug-
gesting that the lipid rafts used by EVs may be caveolae-
independent (26,41). The potential roles of some proteins
involved in this process are also being identified. For
example, annexin II may have a role in anchoring of EVs
to lipid raft domains of the plasma membrane whilst
annexin-VI may contribute to the trafficking of EVs to the
late endosomal compartment (47). These findings support
the hypothesis that lipid rafts are involved in the EV
uptake mechanism; the scale and precise mechanisms of
this route into cells remains to be elucidated.
Cell surface membrane fusion
Another possible entry mechanism is via direct fusion of
the EV membrane with the cell plasma membrane (34).
Fusion of lipid bilayers in an aqueous environment is a
process whereby 2 initially distinct membranes merge.
The lipid bilayers are brought into close proximity and
the outer-leaflets come into direct contact which leads to
formation of a hemi-fusion stalk with fused outer-leaflets.
Following this, stalk expansion produces the hemi-fusion
diaphragm bilayer from which a fusion pore opens (128
130). As a result, the two hydrophobic cores mix forming
one consistent structure. Several protein families partici-
pate in this process including SNAREs, Rab proteins, and
Sec1/Munc-18 related proteins (SM-proteins) (131).
Fusion of membranes can be observed in various ways,
including via fluorescent lipid dequenching. This tech-
nique was applied to study the uptake of EVs from
melanoma cells, the results suggested that at least some
of the vesicles are able to fuse with the recipient cell
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(34); this fusion was enhanced under acidic conditions.
Similarly, when the dequenching method was used to
demonstrate fusion of R18-labelled EVs with the plasma
membrane of bone marrow-derived dendritic cells (22).
The delivery of miRNAs and luciferin to the cytosol of
the recipient cells provides further evidence of fusion of
EVs with either the plasma or endosomal membrane (22).
The lipid raft-like membrane composition of EVs may
aid their fusion with recipient cell membranes (132). EV-
cell fusion may be limited to acidic pH conditions which
are present in endosomes, perhaps owing to differences
in lipid content or overall ionic charge of the EV surface
following release (34). The body of research supporting a
primarily endocytic mechanism for EV uptake makes it
unlikely that fusion is the main entry route, but a fusion-
based pathway cannot be ruled out. Future work will be
needed to ascertain the extent to which fusion-based EV
entry occurs under physiological conditions.
Cell-specific EV uptake
One question currently vexing the EV field is whether
or not EV uptake is a cell typespecific process. Results
from some studies show that fluorescently labelled EVs
can be taken up by virtually every cell type tested (26,38),
whereas others suggest that vesicular uptake is a highly
specific process which can only occur if cell and EV share
the right combination of ligand and receptor. Hetero-
geneity in the donor/recipient cells, EVs, experimental
setup and the context of experiments will all affect the
outcome, and may thus account for the observed dis-
crepancies. However, there are certainly examples of cell-
type specific uptake. Pancreatic adenocarcinomaderived
EVs were shown to be internalized most efficiently by
peritoneal exudate cells and less proficiently in granulo-
cytes and T-cells (38). Tspan8 containing lymph node
stromaderived EVs were most effectively internalized
by endothelial cells and pancreatic cells but to a lower
degree by parental lymph node stroma cells (37). In some
cases, the basis for a specific interaction may have been
elucidated. For example, milk EVs can be taken up via
monocyte-derived dendritic cells thanks to the interaction
between DC-SIGN and MUC1, whereas EVs derived
from other sources and lacking MUC1 were unable to
enter these cells (29). Treatment with an RGD peptide
(which can block integrin-mediated receptor internali-
zation) reduced EV uptake in dendritic cells (30) and
macrophages (23), but did not inhibit EV uptake by
microglia (28). This indicates that multiple mechanisms
are responsible for EV-cell communication and different
combinations of EV communication strategies are used
by different cell types.
Conclusions and future directions
A growing body of evidence suggests that EVs are in-
volved in normal homeostasis (133) and are deregulated in
disease (51). EVs, which are released in greater numbers
by cancer cells (134), can promote tumour development
and are involved in mediating intercellular communica-
tion within the tumour microenvironment (135). Further
advancing our understanding of both the EV uptake
mechanism and characterization of disease-promoting
EVs will enable development of therapeutic strategies to
inhibit interactions between such EVs and healthy reci-
pient cells (136). EVs are also being explored as natural
vectors for therapeutic delivery, with some early studies
showing great potential (20,137,138). Improved under-
standing of the EV uptake mechanism will therefore
benefit design of novel and sophisticated drug delivery
systems.
To this end, we have reviewed here the mechanisms
by which EVs are internalized by cells. Endocytosis, in
its various guises, appears to be the primary method of
entry by EVs. There appears to be little agreement in
the literature as to which type of endocytic mechanisms
are most important, with clathrin-dependent, caveolae-
dependent, macropinocytosis, phagocytosis and lipid raft
mediated uptake variously described as being prevalent.
These differences reflect the heterogeneity both in EV
populations and in the cell types being used. It is possible
that a population of EVs can simultaneously trigger a
number of different gateways into a cell, with the primary
entry points depending on the cell type and EV consti-
tuents (29,37,38). This would also explain why inhibition
of any given pathway rarely leads to a complete abroga-
tion of EV entry (2325,27,34,38,4042,44,45,81). There
are also potential problems with the use of some
inhibitors that have known (or potentially unknown)
cross-reactivity with multiple pathways. For example,
cytochalasin D inhibits actin polymerization and so the
finding that it reduces EV uptake has been used to
support an endocytic uptake pathway for vesicles (139).
However, the global cellular effects of disrupting the
actin cytoskeleton are profound. The reduced EV uptake
caused by cytochalasin D could therefore be caused
indirectly via perturbation of other cellular processes,
such as cellular polarization (140), migration or cell cycle
(141). Similarly, PI3K has a multitude of roles within
various cell-signalling networks (142). PI3K signalling has
been implicated in phagocytic uptake (143). The reduced
EV uptake observed following treatment of recipient cells
with the PI3K inhibitors wortmannin and LY294002
could be independent of any effects on phagocytosis,
and instead caused indirectly by the deregulation of
other processes such as migration, cell growth, or motility
(144,145). There is also overlap in the pathways that such
inhibitors can affect. For example, inhibiting PI3K can
perturb both phagocytosis and macropinocytosis (146).
Dynamin2 is involved in both CME and CDE, so its inhi-
bition cannot easily distinguish between these 2 processes
(147,148). MbCD causes depletion of cholesterol and can
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cause a decrease in both lipid raftmediated uptake as
well as caveolin-dependent internalization. Furthermore,
MbCD has substantial effects across a range of cellular
functions, including effects that are independent of cho-
lesterol chelation (149). The results of studies using small
molecular inhibitors are important contributions towards
understanding the EV uptake puzzle, but the pleiotropic
nature of these compounds means that interpretation of
such data must be tempered with extreme caution.
Large areas of plasma membrane are naturally re-
cycled as part of normal cellular maintenance (150).
Indeed, an area equivalent to the entire surface of the cell
can be internalized and replenished every few hours
(151). It could be expected that EVs bound at the cell
surface would eventually be internalized as part of this
normal membrane recycling. In such a scenario, it would
stand to reason that inhibiting any of the processes that
regulate membrane recycling would also reduce EV
uptake. The results of the small molecule inhibitor experi-
ments described above (28) could therefore be explained
by their effects on membrane recycling rather than by their
proposed ability to affect a direct EV uptake pathway.
However, the rapidity of EV uptake would argue against
this model of ‘‘passive endocytosis.’’ The ability to inhibit
uptake with antibodies that block specific protein
protein interactions also suggest that internalization is
an active process. Nevertheless, these arguments all
highlight the complexities in studying vesicular uptake.
It is also worth mentioning that there are several other
clathrin-independent endocytic pathways, such as the
recently described CLIC/GLEEC pathway (78,152). The
extent to which these other pathways may be involved
remains to be determined.
Whilst EV uptake leads to the delivery of nucleic acids
and protein, internalization is not always necessary to
elicit a phenotypic response. Receptorligand interactions
which take place on the cell surface may be sufficient;
for example, interaction of soluble ligands (produced by
proteolytic cleavage of EV membrane proteins) with cell
receptors may successfully permit signal transduction and
subsequent downstream signalling effects in the reci-
pient cell (153155). In another study, uptake of EVs by
phagocytosis was not actually essential for the induction
of cytokine IL-1b secretion suggesting that EV-associated
fibronectin surface receptor interaction is sufficient to
direct this activity (23). Interestingly, EVs may stimulate
MAPK signalling leading to altered activity within the
recipient cell (25,104). Indeed, pharmacological inhibition
of ERK1/2 actually inhibited EV uptake, suggesting that
these signalling pathways may also be involved in EV
uptake (25).
In this review, we have focused on the mechanisms of
exosomal uptake. However, there exists a range of types
and sizes of EV. Many preparations of vesicles used in
studies contain heterogeneous collections of such vesicles.
This heterogeneity probably contributes to the differences
in apparent internalization mechanisms observed in
various studies, as well as the lack of a single clear up-
take route in any given study. Our ability to pinpoint the
uptake route for different vesicles of similar sizes is still
limited by a lack of biochemical markers to characterize
and isolate them. As this knowledge increases the means
by which they enter cells will be unravelled.
Understanding of EV internalization is a key goal of
the fledgling EV field. Despite the EV research field still
being in its infancy and the limited number of relevant
studies performed to date, the discoveries concerning
EV uptake made so far are promising for future research.
The potential that EVs have shown as therapeutic agents
means that it is imperative that the EV uptake mechanism
is understood to aid prospective therapeutic design. Exci-
tingly, EV research is continually expanding and devel-
oping, therefore greater understanding of the EV uptake
pathway is certainly achievable in the foreseeable future.
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